共 50 条
Can We Cure Atherosclerosis?
被引:18
|作者:
Robinson, Jennifer G.
[1
,2
,3
]
Davidson, Michael H.
[4
]
机构:
[1] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA 52242 USA
[2] Univ Iowa, Dept Med, Coll Publ Hlth, Iowa City, IA 52242 USA
[3] Carver Coll Med, Iowa City, IA 52242 USA
[4] Univ Chicago Med, Dept Cardiol, Chicago, IL USA
关键词:
Atherosclerosis;
Regression;
Primary prevention;
Familial hypercholesterolemia;
Apolipoprotein B lipoproteins;
PCSK9 monoclonal antibodies;
Statins;
LONG-TERM RISK;
FAMILIAL HYPERCHOLESTEROLEMIA;
LDL CHOLESTEROL;
STATIN THERAPY;
EFFICACY;
SAFETY;
DISEASE;
METAANALYSIS;
PROGRESSION;
EVOLOCUMAB;
D O I:
10.3909/ricm19S1S0003
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Cardiovascular disease mortality rates have begun to rise in the United States. Based on the large body of supportive evidence, we propose a proof-of-concept, first-in-human trial to cure atherosclerosis: CURing Early ATHEROsclerosis (CURE ATHERO). This trial is based on a model of intensive induction therapy for extensive, if not complete, plaque regression, followed by intermittent maintenance therapy. An extensive body of evidence has demonstrated the causal role of apolipoprotein B lipoproteins in atherosclerosis progression and data suggest intensive low-density lipoprotein cholesterol (LDL-C) lowering may have a substantial impact on earlier stages of atherosclerosis. Compared with lifetime treatment to prevent atherosclerosis progression, this induction-intermittent treatment model will minimize costs and maximize adherence and safety. (C) 2018 MedReviews (R), LLC
引用
收藏
页码:S20 / S24
页数:5
相关论文